The European Journal of Health Economics

2002 - 2025

Current editor(s): J.-M.G.v.d. Schulenburg

From:
Springer
Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ)
Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 6, issue 4, 2005

How much are health-care systems prepared to pay to produce a QALY? pp. 285-287

Martin Buxton

Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris pp. 288-297

Helen Campbell, Sue Tait, Linda Sharples, Noreen Caine, Timothy Gray, Peter Schofield and Martin Buxton

Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? pp. 298-308

L. Di Matteo and R. Di Matteo

Indirect costs of cervical and breast cancers in Spain pp. 309-313

Juan Oliva, Félix Lobo, Julio López-Bastida, Néboa Zozaya and Rosa Romay

Discrete choice experiments in health economics: Distinguishing between the method and its application pp. 314-316

Emily Lancsar and Cam Donaldson

Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany pp. 317-321

Werner Kulp, Johann Graf von der Schulenburg and Wolfgang Greiner

Hospital development plans pp. 322-333

Steffen Fleßa

Can economic evaluations be made more transferable? pp. 334-346

Stephanie Boulenger, John Nixon, Michael Drummond, Philippe Ulmann, Stephen Rice and Gerard Pouvourville

Estimating utility data from clinical indicators for patients with stable angina pp. 347-353

Louise Longworth, Martin Buxton, Mark Sculpher and David Smith

The cost-effectiveness of dual oral antiplatelet therapy following percutaneous coronary intervention pp. 354-362

Anna Ringborg, Peter Lindgren and Bengt Jönsson

Volume 6, issue 3, 2005

Health economic evaluation of disease management programs pp. 191-196

Wolfgang Greiner

The economic and quality of life impact of hypoglycemia pp. 197-202

Jonas Lundkvist, Christian Berne, Björn Bolinder and Linus Jönsson

Use of a decision analysis model to assess the medicoeconomic implications of FDG PET imaging in diagnosing a solitary pulmonary nodule pp. 203-214

Catherine Lejeune, Kazem Al Zahouri, Marie-Christine Woronoff-Lemsi, Patrick Arveux, Alain Bernard, Christine Binquet and Francis Guillemin

Institutional arrangements and efficiency of health care delivery systems pp. 215-222

Vasanthakumar Bhat

A cross-national perspective on cost of illness pp. 223-232

Johan Polder, Willem Meerding, Luc Bonneux and Paul Maas

An empirical analysis of tobacco addiction in Italy pp. 233-243

Silvia Tiezzi

Influenza treatment with neuraminidase inhibitors pp. 244-252

Beate Sander, Marlene Gyldmark, Frederick Hayden, James Morris, Elvira Mueller and Rito Bergemann

Measuring health-related utility pp. 253-260

Stirling Bryan and Louise Longworth

Comparison of general practitioner records and patient self-report questionnaires for estimation of costs pp. 261-266

Hema Mistry, Martin Buxton, Louise Longworth, Judy Chatwin and Robert Peveler

The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland pp. 267-273

Lesley Tilson, Kathleen Bennett and Michael Barry

Reimbursement and clinical guidance for pharmaceuticals in Sweden pp. 274-279

Anders Anell and Ulf Persson

Volume 6, issue 2, 2005

Practice guidelines based on clinical and economic evidence pp. 91-93

Frans Rutten, Werner Brouwer and Louis Niessen

Costs of hospitalization for severe acute asthma of patients not treated according to guidelines and recommendations pp. 94-101

Jean-Claude Sailly, Xavier Lenne, Caroline Bercez, Thérèse Lebrun, Antoine-Bernard Tonnel and Isabelle Tillie-Leblond

Cost of home palliative care compared with conventional hospital care for patients with haematological cancers in Greece pp. 102-106

Sofia Tzala, Joanne Lord, Nikolaos Ziras, Panayotis Repousis, Anna Potamianou and Evangelia Tzala

Time preference bias in time trade-off pp. 107-111

Marjon van der Pol and Larissa Roux

Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany pp. 112-123

Uwe Siebert, Gaby Sroczynski, Juergen Wasem, Wolfgang Greiner, Ulrike Ravens-Sieberer, Pamela Aidelsburger, Bärbel Kurth, Monika Bullinger, J.-Matthias Schulenburg, John Wong and Siegbert Rossol

Validating the EQ-5D with time trade off for the German population pp. 124-130

W. Greiner, C. Claes, J. J. V. Busschbach and Johann Graf von der Schulenburg

Spatial competition for quality in the market for hospital care pp. 131-135

Marcello Montefiori

Cost-effectiveness of venlafaxine XL compared with diazepam in the treatment of generalised anxiety disorder in the United Kingdom pp. 136-145

J. Guest, J. Russ and A. Lenox-Smith

Order bias in estimates of willingness to pay for drugs to treat attention-deficit/hyperactivity disorder pp. 146-151

Annemieke De Ridder and Diana De Graeve

Risk and potential risk reduction in diabetes type 2 patients in Germany pp. 152-158

Bertram Häussler, Ursula Berger, Oliver Mast and Wolfgang Thefeld

Economic burden of hepatitis C in Canada and the potential impact of prevention pp. 159-165

Susie El Saadany, Douglas Coyle, Antonio Giulivi and Mohammad Afzal

The direct medical cost of diabetes in Israel pp. 166-171

Gabriel Chodick, Anthony Heymann, Francis Wood and Ehud Kokia

The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation pp. 172-182

Christophe Legendre, Stephen Beard, Anne Crochard, Yvon Lebranchu, Claire Pouteil-Noble, Anke Richter and Isabelle Durand-Zaleski

German health care system in transition pp. 183-187

Johann Graf von der Schulenburg

Volume 6, issue 1, 2005

Defining the “Health Benefit Basket” in nine European countries pp. 2-10

Jonas Schreyögg, Tom Stargardt, M. Velasco-Garrido and R. Busse

Criteria for determining a basic health services package pp. 2-7

E. Stolk and M. Poley

Consumer preferences in social health insurance pp. 8-15

Jan Kerssens and Peter Groenewegen

The “Health Benefit Basket” in Denmark pp. 11-17

Lone Bilde, Anni Ankjaer-Jensen and Bent Danneskiold-Samsøe

Modeling the economic burden of diseases imputable to stress at work pp. 16-23

Sophie Béjean and Hélène Sultan-Taïeb

Does the English NHS have a ‘Health Benefit Basket’? pp. 18-23

Anne Mason

The “Health Benefit Basket” in France pp. 24-29

Martine Bellanger, Veneta Cherilova and Valérie Paris

The cost-effectiveness of human papillomavirus screening for cervical cancer pp. 30-37

Jeremy Holmes, Lindsay Hemmett and Susan Garfield

Determining the “Health Benefit Basket” of the Statutory Health Insurance scheme in Germany pp. 30-36

Reinhard Busse, Tom Stargardt and Jonas Schreyögg

Benefits and entitlements in the Hungarian health care system pp. 37-45

Peter Gaal

Collecting unit cost data in multicentre studies pp. 38-44

Sarah Wordsworth, Anne Ludbrook, Fergus Caskey and Alison Macleod

Bayesian regression models for cost-effectiveness analysis pp. 45-52

Francisco-José Polo, Miguel Negrín, Xavier Badía and Montse Roset

The “Essential Levels of Care” in Italy: when being explicit serves the devolution of powers pp. 46-52

Aleksandra Torbica and Giovanni Fattore

Substance abuse treatment, what do we know? pp. 53-64

Matilde Machado

The “Health Benefit Basket” in The Netherlands pp. 53-57

Elly Stolk and Frans Rutten

Definition of the “Health Benefit Basket” in Poland pp. 58-65

Adam Kozierkiewicz, Wojciech Trąbka, Artur Romaszewski, Krzysztof Gajda and Dariusz Gilewski

A modified three-stage data envelopment analysis pp. 65-72

Jos Blank and Vivian Valdmanis

Spanish health benefits for services of curative care pp. 66-72

Ivan Planas-Miret, Ana Tur-Prats and Jaume Puig-Junoy

A ‘new and improved’ EQ-5D valuation questionnaire? pp. 73-82

Nancy Devlin, Paul Hansen, Peter Herbison and Susan Macran

On the (mis)use of cross-price effects to gauge the effectiveness of smokeless tobacco in smoking cessation pp. 83-86

Richard Ault, Thomas Beard, John Jackson and Richard Saba